1. ALLA AKTIER
  2. NYHETER
  3. SYNACT PHARMA

SynAct Pharma

Nyheter SynAct Pharma Nyheter alla bolag
Affiliate
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här
Erbjudandet gäller nya kunder och omfattar handel via Nordnets app eller hemsida i nordiska aktier, ETF:er, teckningsrätter och teckningsoptioner. För fullständiga villkor se nordnet.se/jubileum. Kom ihåg att investeringar alltid innebär en risk.

Synact Pharma large shareholder trading update

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced, that the company has been informed by a large shareholder, that a trade of up to approximately 1 million shares was placed on the market Monday, May 25, due to an operational error between the bank and a private shareholder. The shareholder has informed Synact Pharma that the situation was identified and corrected, and that the order was cancelled by the bank shortly thereafter.

For further information, please contact:
Jeppe Øvlesen
CEO, SynAct Pharma AB
Phone: + 45 2844 7567
E-mail: investor.relations@synactpharma.com

About SynAct Pharma AB
SynAct Pharma AB (Nasdaq Stockholm: SYNACT) is a clinical stage biotechnology company focused on the resolution of inflammation through the selective activation of the melanocortin system. The company has a broad portfolio of oral and injectable selective melanocortin agonists aimed at inducing anti-inflammatory and inflammation resolution activity to help patients achieve immune balance and overcome their inflammation. For further information: https://synactpharma.com/.

Attachments
Synact Pharma large shareholder trading update

Datum 2026-05-26, kl 08:58
Källa MFN
Bifogade filer
Synact Pharma large shareholder trading update